These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 22414090)

  • 1. Bcl-2 inhibitors: emerging drugs in cancer therapy.
    Bodur C; Basaga H
    Curr Med Chem; 2012; 19(12):1804-20. PubMed ID: 22414090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bcl-2 family members as molecular targets in cancer therapy.
    Marzo I; Naval J
    Biochem Pharmacol; 2008 Oct; 76(8):939-46. PubMed ID: 18638457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autophagy contributes to modulating the cytotoxicities of Bcl-2 homology domain-3 mimetics.
    Yu L; Liu S
    Semin Cancer Biol; 2013 Dec; 23(6 Pt B):553-60. PubMed ID: 24012660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PPARγ agonist rosiglitazone sensitizes the BH3 mimetic (-)-gossypol to induce apoptosis in cancer cells with high level of Bcl-2.
    Li X; He J; Li B; Gao M; Zeng Y; Lian J; Shi C; Huang Y; He F
    Mol Carcinog; 2018 Sep; 57(9):1213-1222. PubMed ID: 29856104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy.
    Suvarna V; Singh V; Murahari M
    Eur J Pharmacol; 2019 Nov; 862():172655. PubMed ID: 31494078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging Bcl-2 inhibitors for the treatment of cancer.
    Azmi AS; Wang Z; Philip PA; Mohammad RM; Sarkar FH
    Expert Opin Emerg Drugs; 2011 Mar; 16(1):59-70. PubMed ID: 20812891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small-molecule BH3 mimetics to antagonize Bcl-2-homolog survival functions in cancer.
    Goldsmith KC; Hogarty MD
    Curr Opin Investig Drugs; 2009 Jun; 10(6):559-71. PubMed ID: 19513945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The BCL-2 protein family, BH3-mimetics and cancer therapy.
    Delbridge AR; Strasser A
    Cell Death Differ; 2015 Jul; 22(7):1071-80. PubMed ID: 25952548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules.
    Yap JL; Chen L; Lanning ME; Fletcher S
    J Med Chem; 2017 Feb; 60(3):821-838. PubMed ID: 27749061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small-molecule inhibitors of Bcl-2 family proteins as therapeutic agents in cancer.
    Mohammad R; Giri A; Goustin AS
    Recent Pat Anticancer Drug Discov; 2008 Jan; 3(1):20-30. PubMed ID: 18289121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-molecule inhibitors of Bcl-2 family proteins are able to induce tumor regression in a mouse model of pre-B-cell acute lymphocytic lymphoma.
    Turner BC; Eves T; Refaeli Y
    DNA Cell Biol; 2008 Mar; 27(3):133-42. PubMed ID: 18163880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New dimension in therapeutic targeting of BCL-2 family proteins.
    Besbes S; Mirshahi M; Pocard M; Billard C
    Oncotarget; 2015 May; 6(15):12862-71. PubMed ID: 25970783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic inhibition of BCL-2 and related family members.
    Levy MA; Claxton DF
    Expert Opin Investig Drugs; 2017 Mar; 26(3):293-301. PubMed ID: 28161988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [BH3 mimetics as a strategy to complement anticancer therapies].
    Hartman MŁ; Czyż M
    Postepy Hig Med Dosw (Online); 2012 Feb; 66():67-77. PubMed ID: 22371408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs targeting Bcl-2 family members as an emerging strategy in cancer.
    Leber B; Geng F; Kale J; Andrews DW
    Expert Rev Mol Med; 2010 Sep; 12():e28. PubMed ID: 20822554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multifaceted anticancer activity of BH3 mimetics: Current evidence and future prospects.
    Opydo-Chanek M; Gonzalo O; Marzo I
    Biochem Pharmacol; 2017 Jul; 136():12-23. PubMed ID: 28288819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the B-cell lymphoma/leukemia 2 family in cancer.
    Davids MS; Letai A
    J Clin Oncol; 2012 Sep; 30(25):3127-35. PubMed ID: 22649144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the Bcl-2.
    Patel MP; Masood A; Patel PS; Chanan-Khan AA
    Curr Opin Oncol; 2009 Nov; 21(6):516-23. PubMed ID: 19730103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcl-2 Antiapoptotic Family Proteins and Chemoresistance in Cancer.
    Maji S; Panda S; Samal SK; Shriwas O; Rath R; Pellecchia M; Emdad L; Das SK; Fisher PB; Dash R
    Adv Cancer Res; 2018; 137():37-75. PubMed ID: 29405977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer.
    Doshi JM; Tian D; Xing C
    J Med Chem; 2006 Dec; 49(26):7731-9. PubMed ID: 17181155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.